Elaine B. Cadogan

机构：AstraZeneca (Singapore) · ORCID：0000-0002-9757-8305

发表论文 130 篇 · 总被引 3060 次 · h-index 26

代表论文

• Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing (2023 · Nature Communications · 被引 136)
• The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment (2024 · Nature Communications · 被引 64)
• Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood–Brain Barrier: The Discovery of AZD1390 (2024 · Journal of Medicinal Chemistry · 被引 16)
• Use of Direct-to-Biology Strategies for the Discovery of 2′-Deoxynucleoside 5′-Monophosphate N-Glycosidase (DNPH1) PROTACs (2025 · Journal of Medicinal Chemistry · 被引 10)
• Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models (2023 · Cancers · 被引 9)
• Selective DNA-PK Inhibition Enhances Chemotherapy and Ionizing Radiation Activity in Soft-Tissue Sarcomas (2023 · Clinical Cancer Research · 被引 8)